Free tool, no sign-up
Enter your height, weight and health conditions to see which GLP-1 medications you meet the FDA label criteria for. Then get the part most checkers skip: the honest picture on insurance, prior authorization and cash prices.
Built for the US. In the UK? Use our UK checker instead.
Enter your height and weight to see where you stand.
This is general information based on FDA label criteria and published prices, for adults. It is not medical advice, a diagnosis, or a guarantee of insurance coverage. Only a clinician can decide whether a medication is right for you, and only your plan can confirm what it covers. Last reviewed October 2026.
For weight loss, the Zepbound, Wegovy and Foundayo labels are for adults with obesity, or with overweight and at least one weight-related condition. In the trials behind them, obesity meant a BMI of 30 or higher, and overweight meant a BMI of 27 to 29.9 with at least one weight-related condition.
| Your BMI before you started treatment | Meets the weight-loss label for Zepbound, Wegovy and Foundayo? |
|---|---|
| 30 or higher | Yes |
| 27 to 29.9 | Yes, with at least one weight-related condition, such as high blood pressure, type 2 diabetes, high cholesterol, sleep apnea or heart disease |
| Under 27 | No, not for weight loss |
Already on treatment, and your BMI has dropped? Eligibility is usually judged on your BMI before you started (the Medicare GLP-1 Bridge form asks for exactly that), and the labels cover keeping weight off long term, so a lower BMI now doesn't mean you've stopped meeting them.
Other approvals have their own tests: Zepbound for moderate to severe obstructive sleep apnea in adults with obesity; the Wegovy injection to lower the risk of heart attack, stroke and heart-related death in adults with heart disease who also have obesity or overweight, for weight loss in children aged 12 and older with obesity, and for MASH (a liver disease) with moderate to advanced scarring. Meeting a label isn't the same as being covered by insurance, and only a clinician can decide whether a medicine is right for you.
Every GLP-1 sold for weight loss in the US uses the same two-line test, straight from the FDA labels: a BMI of 30 or higher, or 27 or higher with at least one weight-related condition like high blood pressure, type 2 diabetes, high cholesterol, sleep apnea or heart disease. That's it. Zepbound, Wegovy (pen and pill) and Foundayo all use it.
Most online checkers stop there and drop you into a telehealth checkout. But the harder question in America isn't whether you qualify. It's who pays. So here's where things actually stand, checked October 5, 2026.
Coverage varies wildly from plan to plan. Many still exclude weight loss drugs outright, and the plans that do cover them almost always want prior authorization first, where your clinician documents your BMI and conditions. Some add step therapy on top. If your plan does cover the drug, a manufacturer savings card does the heavy lifting: as little as $25 a month for Wegovy, Zepbound or Foundayo. The Wegovy and Zepbound cards save at most $100 a month, so a big copay can still leave you a bill. How each card works: the Zepbound savings card and the Wegovy savings card.
Medicare Part D has excluded weight loss drugs by law for decades. From July 1, 2026 through December 31, 2027, the Medicare GLP-1 Bridge changes that: eligible Part D enrollees pay a flat $50 a month for Wegovy (injection or pill), Foundayo, or the Zepbound KwikPen. Two catches: savings cards legally can't be used with government programs, and the $50 copays don't count toward your Part D deductible or out-of-pocket cap. Medicaid coverage for obesity is still a state-by-state patchwork.
This is where 2026 got interesting. The manufacturers now sell direct: LillyDirect has Zepbound at $299 to $449 a month (refill within 45 days each time or higher doses revert to standard rates) and Foundayo at $149 to $299. NovoCare Pharmacy has the Wegovy injection at $349 a month ($399 for the top 7.2 mg dose, and $199 for a new patient's first two fills of the starter doses), and the Wegovy pill at $149 to $299. Nobody needs to pay the $1,000-plus list prices anymore. Every dose and a year's cost: what Zepbound costs without insurance and what Wegovy costs without insurance.
Ro, LifeMD, Hims & Hers, Noom Med and WeightWatchers Clinic all prescribe the branded medications now, at the manufacturers' cash prices plus their own visit or subscription fee. Hims & Hers has sold branded Wegovy since March 2026, after Novo Nordisk dropped its lawsuit over compounded copies. The FDA has been shutting mass compounding down since it declared the shortages resolved, so be wary of anything priced below the manufacturers' own numbers. What you're buying from telehealth is speed and convenience, not a lower drug price.
If you have insurance, your own doctor is often the best first stop. They know your history, the visit usually bills to your plan, and they're the one who files the prior authorization anyway. Bring your numbers from the checker above and ask directly: do I meet my plan's criteria, and what does it want documented?
Whichever route you take, the thing that makes the medication work is the boring part: eating enough protein, keeping muscle, and tracking your weight, doses and food so you can see what's happening. That's what Healthcount is for, and a free account takes about a minute.
What do they cost?
List prices, cash prices, savings cards and the $50 Medicare copay, all in one place on our US GLP-1 price guide.
Using Zepbound vials?
Convert between syringe units, mL and mg with our Zepbound units calculator.
The label criteria come from the FDA prescribing information for each medication, and the prices from the manufacturers' own pages and reporting. Checked October 5, 2026. Prices keep moving, so confirm on lilly.com or novocare.com before you plan around a number.
This page is general information for adults, not medical advice, a diagnosis, or a guarantee of insurance coverage. Eligibility and coverage are decisions for you, your clinician and your plan.